{
    "clinical_study": {
        "@rank": "134430", 
        "arm_group": {
            "arm_group_label": "All participants", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Open label, single arm dose finding trial with two treatment strata ( high-TBI and low-TBI\n      conditioning regimens) to assess the efficacy of Treg/Tcon addback to CD34 selected\n      partially matched related donor stem cells. The maximum tolerated dose will be established\n      using 3 patients per cohort and there will be an expansion cohort at the MTD."
        }, 
        "brief_title": "Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "High Risk Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Age 0-70 years 2. Karnofsky or Lansky Performance status >70% 3. High risk hematologic\n        malignancy (see section 5.1) 4. Acute myeloid leukemia (AML) with one or more of the\n        following criteria: 4a.Poor risk cytogenetics, including -5, 5q-, -7, 7q-, t(9;22);\n        complex cytogenetics (>3 abnormalities); or normal cytogenetics with Flt3 ITD and no NPM1\n        mutation,  in first or subsequent complete remission (CR).\n\n        4b. Relapsed or primary refractory AML with <10% blasts in the peripheral blood.\n\n        4c. Patients in CR1 who required two cycles of induction to achieve remission may be\n        included at the discretion of the treating physician.\n\n        4d. Standard risk or intermediate risk cytogenetics in second or subsequent CR (enrolled\n        at the discretion of the treating physician).\n\n        5. Acute lymphoblastic leukemia (ALL) with one of the following criteria: 5a. Second or\n        subsequent CR 5b. Any PR (no circulating blasts) 5c. High-risk ALL in first CR including\n        (Ph+, t(4:11), complex karyotype, hypodiploidy (<44 chromosomes), or positive MRD after\n        induction 6. Myelodysplasia, intermediate -2 (score 1.5-2.0) or high risk (score >2.5) by\n        the International Prognostic Score System.\n\n        7. Myeloproliferative Disorders (include CMML, AMM or Idiopathic Myelofibrosis, and JMML)\n        with excess blasts (>5%) 8. Chronic myeloid leukemia (CML) with one of the following\n        criteria: 8a. Second or subsequent chronic phase 8b. Accelerated phase 8c. blast crisis 9.\n        Non-Hodgkin's lymphoma (NHL) meeting one of the following criteria: 9a. Relapse after\n        autologous stem cell transplantation with evidence of responsive disease.\n\n        9b. Patient with chemosensitive relapse who have no option for autologous stem cell\n        transplantation due to blood or marrow involvement or failure to mobilize autologous stem\n        cells or are not considered eligible for autologous transplant by their treating\n        physician.\n\n        9c. Hodgkin's Lymphoma: relapse after autologous HCT, chemo-refractory disease\n\n        10. No suitable HLA-identical sibling donor. 11. No identified 8/8 (based upon A, B, C,\n        DRB1 loci) allele matched unrelated donor, or unable to wait sufficient time to procure a\n        8/8 allele matched unrelated donor 12. Available HLA 3-5/6 matched genotypically\n        haploidentical partially matched related donor 13. Female patients must be surgically\n        sterile, postmenopausal (minimum 1 year without menses), or agree to use approved form of\n        contraception from the time of signing the informed consent form through Day +100. Male\n        patients must also agree to use an approved form of birth control for either themselves or\n        their partner, as appropriate, from the time of signing the informed consent form through\n        Day +100.\n\n        14. Able to provide informed consent and have signed an approved consent form that\n        conforms to federal and institutional guidelines.\n\n        Exclusion Criteria:\n\n          1. Available HLA identical matched sibling donor (unless having failed a prior\n             allogeneic transplant from an HLA identical matched sibling)\n\n          2. Recipient HLA antibodies against donor HLA\n\n          3. Any of the following organ dysfunctions:\n\n               1. Cardiac- left ventricular ejection fraction <40%, symptomatic coronary artery\n                  disease, or uncontrolled arrhythmias\n\n               2. Pulmonary- FEV1 or DLco<40% or need for use of supplemental oxygen\n\n               3. Renal- calculated or measured GFR <30 ml/min, dialysis requirement, or prior\n                  renal transplant\n\n               4. Hepatic- bilirubin > 2 X ULN, ALT> 2.5 X ULN, cirrhosis\n\n          4. Patients with active or uncontrolled bacterial, viral, or fungal infections requiring\n             systemic therapy.\n\n          5. Patients who have tested positive for HIV.\n\n          6. Pregnant women, nursing mothers or women of child-bearing potential who are unwilling\n             to use medically accepted methods of contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818479", 
            "org_study_id": "HCI61077"
        }, 
        "intervention": [
            {
                "arm_group_label": "All participants", 
                "description": "Open label, single arm dose finding trial with two treatment strata ( high-TBI and low-TBI conditioning regimens) to assess the efficacy of Treg/Tcon addback to CD34 selected partially matched related donor stem cells.", 
                "intervention_name": "stem cell transplant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "All participants", 
                "intervention_name": "Stem cell transplant", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84112"
                }, 
                "name": "Huntsman Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Michael Boyer, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies", 
        "overall_contact": {
            "email": "karen.pena@hci.utah.edu", 
            "last_name": "Karen Pena", 
            "phone": "801-213-4233"
        }, 
        "overall_contact_backup": {
            "email": "andrea.gurule@hci.utah.edu", 
            "last_name": "Andrea Gurule", 
            "phone": "801-581-4467"
        }, 
        "overall_official": {
            "affiliation": "Huntsman Cancer Institute", 
            "last_name": "Michael Boyer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of acute GVHD grade II-IV at Day +100 post transplant Absolute CD4+ count at day +100", 
            "measure": "Rate of acute GVHD", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Day +28 and +100 neutrophil engraftment", 
                "measure": "rate of Engraftment", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "Day +100 and one year survival Day +100 and one year transplant related mortality Day +100 and one year relapse rates", 
                "measure": "Survival at Day 100", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}